|
ISIN No
|
INE597C01021
|
BSE Code / NSE Code
|
532041 / HINDBIO
|
Book Value (Rs.)
|
0.70
|
Face Value
|
2.00
|
|
Bookclosure
|
30/09/2024
|
52Week High
|
10
|
EPS
|
0.00
|
P/E
|
0.00
|
|
Market Cap.
|
7.53 Cr.
|
52Week Low
|
5
|
P/BV / Div Yield (%)
|
10.57 / 0.00
|
Market Lot
|
1.00
|
|
Security Type
|
Other
|
|
The company history sections lists out major chronological events that happened to the company.
| Established in 2000, Hindustan Bio Sciences Limited (HBSL) is an integrated
firm with diversified operations in pharmaceutical and biotechnology sectors.
The company initially commenced operations by sourcing bulk drugs (APIs) and drug intermediates for the Industry with a wellspring of global suppliers and associates.
In the year 2007 the company obtained the import license from Genetic Engineering
Approval Committee (GEAC) for a nephrology product "Recombinant Human
Erythropotien" after conducting clinical trials of the same. The company has been
marketing the niche drug extensively ever since.
The Company to its credit has world class manufacturing facilities for dry and
liquid injectables, liquid/dry syrups, Eye/Ear/Nasal drops, pre-filled syringes and non sterile/sterile ointments, tablets and capsules approved by several regulatory
authorities and is trusted by healthcare professionals and patients across the globe.
2001 - The Company has entered into an agreement with CDSL, NSDL and Venture
Capital & Corporate Investments Ltd (R&T agents) for dematerialisation.
2004 -Hindustan Bio bags GEAC nod recombinant human erythropoietin
2005 -Hindustan Bio Sciences Ltd has received an order for Antiretroviral drug for
a value of Rs 269.30 million from China.
|